GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Unity Biotechnology Inc (STU:9U90) » Definitions » Debt-to-Revenue

Unity Biotechnology (STU:9U90) Debt-to-Revenue : N/A (As of Mar. 2024)


View and export this data going back to 2018. Start your Free Trial

What is Unity Biotechnology Debt-to-Revenue?

Debt-to-Revenue measures a company's ability to pay off its debt.

Unity Biotechnology's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Mar. 2024 was €0.00 Mil. Unity Biotechnology's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Mar. 2024 was €20.80 Mil. Unity Biotechnology's annualized Revenue for the quarter that ended in Mar. 2024 was €0.00 Mil.


Unity Biotechnology Debt-to-Revenue Historical Data

The historical data trend for Unity Biotechnology's Debt-to-Revenue can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Unity Biotechnology Debt-to-Revenue Chart

Unity Biotechnology Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Debt-to-Revenue
Get a 7-Day Free Trial N/A N/A 11.69 213.60 N/A

Unity Biotechnology Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Debt-to-Revenue Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only N/A N/A N/A N/A N/A

Competitive Comparison of Unity Biotechnology's Debt-to-Revenue

For the Biotechnology subindustry, Unity Biotechnology's Debt-to-Revenue, along with its competitors' market caps and Debt-to-Revenue data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Unity Biotechnology's Debt-to-Revenue Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Unity Biotechnology's Debt-to-Revenue distribution charts can be found below:

* The bar in red indicates where Unity Biotechnology's Debt-to-Revenue falls into.



Unity Biotechnology Debt-to-Revenue Calculation

Debt-to-Revenue measures a company's ability to pay off its debt.

Unity Biotechnology's Debt-to-Revenue for the fiscal year that ended in Dec. 2023 is calculated as

Debt-to-Revenue=Total Debt / Revenue
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / Revenue
=(3.165 + 21.585) / N/A
=N/A

Unity Biotechnology's annualized Debt-to-Revenue for the quarter that ended in Mar. 2024 is calculated as

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In the calculation of annual Debt-to-Revenue, the Revenue of the last fiscal year is used. In calculating the annualized quarterly data, the Revenue data used here is four times the quarterly (Mar. 2024) Revenue data.


Unity Biotechnology Debt-to-Revenue Related Terms

Thank you for viewing the detailed overview of Unity Biotechnology's Debt-to-Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.


Unity Biotechnology (STU:9U90) Business Description

Traded in Other Exchanges
Address
285 East Grand Avenue, South San Francisco, CA, USA, 94080
Unity Biotechnology Inc designs therapeutics that prevent, halt, and reverse various diseases of aging. The company focuses on clearing senescent cells, and creating senolytic medicines. Its medicines target vulnerabilities unique to senescent cells to clear those cells from the human body while leaving normal cells unaffected. The firm focuses on age-associated diseases such as osteoarthritis, eye diseases, and pulmonary diseases.

Unity Biotechnology (STU:9U90) Headlines

No Headlines